Pharmaceutical Impurity Control in 2027: CMC Strategy, Regulatory Expectations & Emerging Risks at the 11th Impurities: Genotoxic, Nitrosamine & Beyond Summit I #Egenotoxic 2027

Industry Impact of Nitrosamines - From Crisis to Continuous Control

The discovery of nitrosamine contamination, beginning with the valsartan case, fundamentally reshaped pharmaceutical impurity control. What started as a reactive crisis has now evolved into a continuous, lifecycle-driven challenge requiring deep scientific understanding and cross-functional alignment.

Today, nitrosamines - particularly nitrosamine drug substance-related impurities (NDSRIs) - remain a critical focus, driven by:

• Complex and previously unrecognized formation pathways
• Multi-source contamination (API, excipients, water systems, packaging)
• Ongoing regulatory scrutiny and updated acceptable intake (AI) limits

The industry has moved beyond isolated recalls toward proactive, mechanism-based risk assessment and control strategies.

Regulatory Evolution & CMC Strategy Integration

Regulatory expectations from FDA, EMA, and global authorities continue to intensify, with a clear shift toward:

• Science-based justification over standard thresholds
• Lifecycle impurity management and continuous reassessment
• Inspection readiness and data integrity

Updates to ICH M7 (R2) and Q3D frameworks now require companies to embed impurity control directly into CMC strategy, spanning:

• Drug substance (DS) and drug product (DP) development
• Manufacturing processes and scale-up
• Packaging systems and supply chain control

Success increasingly depends on cross-functional collaboration between CMC, toxicology, analytical, and regulatory teams - ensuring alignment from development through submission and commercialization.

Expanding Scope: Beyond Nitrosamines

As the field evolves, impurity control now extends far beyond traditional nitrosamine focus. At #Egenotoxic 2027, key areas include:

• Advanced genotoxic impurities (GTIs) and cohort of concern substances
• Extractables & leachables (E&L) as a growing source of secondary risks, including nitrosamine formation
• Impurity challenges in biologics, oligonucleotides, and mRNA products
• Interactions between materials, formulation, and manufacturing processes

The summit reflects a broader reality: impurity control is now a system-level challenge, not a single-discipline task.

Advanced Analytics & Predictive Approaches

The next phase of impurity control is driven by technology and data. Industry leaders are adopting:

• Ultra-trace detection methods (sub-ppb level) using next-generation LC-MS
• Real-time and continuous monitoring strategies
• AI-supported impurity profiling and predictive modeling
• Digital toxicology and in silico risk assessment tools

These innovations are transforming impurity control from reactive testing into predictive, design-driven decision-making.

Join #Egenotoxic 2027 and Stay Ahead

Join us on April 7–9, 2027 to:

• Address evolving challenges in nitrosamines, GTIs, and complex impurity profiles
• Strengthen your CMC and regulatory strategy for submissions and inspections
• Explore cutting-edge analytical and predictive technologies
• Gain practical, real-world insights from case studies and regulatory experiences
• Connect with industry leaders, experts, and decision-makers

Secure your place and position your organization for success in an increasingly complex regulatory landscape.Participants at #Egenotoxic 2027 will receive a digital certificate of attendance.